Somnomed (ASX:SOM) — Material Events
ASX:SOM · 7 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
SomnoMed Surpasses $111m Revenue, Eyes 25% Capacity Boost in FY26Medium
SomnoMed FY25 revenue and EBITDA beat guidance; capacity expansion and FDA clearance drive growth
28 Aug 2025
·Full Year Results
·85
SomnoMed Surpasses 1 Million Patients as Revenue Soars 25% in Q4Medium
SomnoMed Q4 FY25 revenue up 25%, capacity expansion underway, 1 million patients treated milestone reached
29 July 2025
·Quarterly Report
·85
SomnoMed Surges with 22% Revenue Growth and FDA-Cleared Rest AssureMedium
SomnoMed FY25 revenue up 22%, EBITDA turns positive; Rest Assure FDA cleared; FY26 guidance raised
28 Aug 2025
·Investor Presentation
·85
SomnoMed Surges with FDA Nod and 22% Revenue Growth in FY25Medium
SomnoMed delivers strong FY25 results, FDA clearance for Rest Assure®, and reaffirms FY26 guidance
27 Nov 2025
·Annual General Meeting Presentation
·85
SomnoMed Reverses Loss with 13% Revenue Growth, Holds Dividend SteadyMedium
SomnoMed posts half-year profit turnaround with 13% revenue growth, no dividend declared
27 Feb 2026
·Half-Year Financial Report
·75
SomnoMed Advances US Clinical Trial as Q1 Revenue Climbs 13.5%Medium
SomnoMed Q1 FY26 revenue up 13.5%, Rest Assure US clinical study advances with FDA support
30 Oct 2025
·Quarterly Activities Report
·75
No articles in this tier for the last 12 months.
Market Mentions
1
- appeared in market wrap coverage
These are market wrap articles where Somnomed (ASX:SOM) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026
28 Feb 2026